European Association of Urology Congress (EAU) 2025 Annual Meeting
EAU 2025 Prostate Cancer
- EAU 2025: Matching-Adjusted Indirect Comparison between Enzalutamide and Darolutamide Doublet Therapy for mHSPC
- EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and Against a Second Taxane
- EAU 2025: A Case of Progression after Triplet Therapy for mHSPC: PARP Inhibitors Alone or in Combination?
- EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: LuPSMA, Who and When?
- EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and Against a Second ARPI
EAU 2025 Bladder Cancer
- EAU 2025: First-in-Human Study of RAG-01, a Novel Small Activating RNA Therapeutic in BCG Failure NMIBC Patients
- EAU 2025: Updated Clinical & Translational Results: BOND-003 Cohort C: A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive NMIBC with CIS
- EAU 2025: Cost-Effectiveness Analysis of Treatments for BCG-Unresponsive High-Risk NMIBC
- EAU 2025: State-of-the-Art Lecture: TAR, a Novel Intravesical Drug Delivery System
- EAU 2025: Translational Correlates Using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Analysis from the BOND-003 and CORE-001 Trials
EAU 2025 Kidney Cancer
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- EAU 2025: State-of-the-art Lecture: Risk Stratification for Patients with mRCC – Is There a Need for New Approaches?
- EAU 2025: Debate – Renal Biopsy for Suspected Renal Cell Carcinoma
- EAU 2025: Debate – Management of Recurrence After Curative Surgery: What is the New Standard of Care? Surgical Resection, Tyrosine Kinase Inhibitors, Immunotherapy, or Radiotherapy?
- EAU 2025: State-of-the-Art Lecture – Screening in RCC: How, When, Who?
EAU 2025 Penile, Urethral, Testicular, and Adrenal Cancers
EAU 2025 Upper Tract Urothelial Carcinoma
EAU 2025 Press Releases
- Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
- Worse Outcomes for Men Who Avoid Prostate Cancer Screening
- Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
- CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates